During our recent consortium meeting, hosted by VB2B, we reviewed project's progress and outlined the next steps in our research.

Over the past few months, we have achieved a key milestone: identifying a number of promising lead targets that may play an important role in the treatment of cardiometabolic diseases.

With this critical step complete, we are now moving into preclinical testing using animal models that closely reflect the human condition. This phase will help us understand how our approach works in a living system and will bring us one step closer to developing a treatment that could make a real difference for patients.